Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

Phase 2CompletedNCT00920790

Kyowa Kirin Co., Ltd.28 enrolled

Overview

To evaluate the efficacy, safety and pharmacokinetic profiles of KW-0761, the anti-CC chemokine receptor 4 (CCR4) antibody, when administered weekly for 8 weeks as an intravenous infusion at a dose of 1.0 mg/kg in relapsed subjects with CCR4-positive adult T-cell leukemia-lymphoma.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Adult T-cell Leukemia-lymphoma

Interventions

KW-0761BIOLOGICAL

KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Positive for serum anti-HTLV-I antibody 2. Acute-, lymphoma-, or chronic-type with poor prognostic factors specified in the past 3. Positive for CCR4 4. Relapsed subject after the response (CR, CRu or PR) in the last previous chemotherapy 5. Received at least one prior chemotherapy 6. Subjects with an interval of four weeks or more between the last day of the previous treatment and the scheduled day of the first KW-0761 treatment 7. PS of 0 to 2 8. Negative for HBs antigen and for HBV-DNA by a real-time PCR Exclusion Criteria: 1. A history of transplantation such as hematopoietic stem cells 2. Positive for HCV antibody or HIV antibody 3. Active multiple cancers at the time of starting this clinical study 4. Previous history of allergic reactions after receiving antibody products 5. Requiring continuous systemic treatment with a steroid 6. Requiring such radiotherapy after starting this clinical study 7. Treated with any investigational drug other than KW-0761 within three months

Locations (1)

Unnamed facility

Tokyo, Japan

Outcomes

Primary Outcomes

Overall Response Rate (ORR)

Response rate defined as the proportion of responders relative to the total population and its exact 95% confidence interval were calculated for best overall response. The antitumor response criteria (Complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD)) were created based on the criteria for non-Hodgkin's lymphoma and chronic lymphocytic leukemia provided in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as well as the criteria for non-Hodgkin's lymphoma by the Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG).Overall Response (OR)= CR + PR.

Time frame: From date of first subject's consent to participate in the study until the date of last protocol-specified examination for last subject completed, assessed up to 14 months.

Pharmacokinetics-Plasma KW-0761 Concentrations

Statistics of plasma KW-0761 concentrations were tabulated. Individual and mean (+standard deviation) plasma KW-0761 concentrations were plotted on a linear and a logarithmic scale against the time of blood sampling. The baseline and maximum time point at which Cmax and Ctrough were collected are 0 to 7 days post-dose.

Time frame: 0 to 7 days post final dose

Pharmacokinetics-Plasma KW-0761 Concentrations (AUC0-7days)

Time frame: 0 to 7 days post final dose

Pharmacokinetics-Plasma KW-0761 Concentrations (t1/2)

Time frame: 0 to 28 days post final dose and follow-up examinations (1 month and 3 months after the end of the post-dosing observation period).

Secondary Outcomes

Progression Free Survival (PFS)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.